On August 21, 2018 Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, reported that it will present data today on its novel T cell therapy technology, TAC-T, during an oral presentation in the Adoptive T Cell Therapies session of the 6th Annual Immuno-Oncology Summit held in Boston (Press release, Triumvira Immunologics, AUG 30, 2018, View Source [SID1234529196]). The presentation will describe the differentiated mechanism of action of the company’s T cell antigen coupler (TAC) technology in preclinical studies demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to traditional CAR-T approaches.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation, entitled: TAC-T: a novel T cell therapy, co-opts the endogenous T cell receptor for effective, safe, and persistent tumor rejection, will be delivered by Christopher Helsen, PhD, Director of Research and Development at Triumvira. Results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against different antigens will be presented. The data suggest that TAC-T cells destroy tumor cells via a mechanism that mimics the natural process of T cell activation. Results clearly demonstrate efficient infiltration and proliferation in solid tumors resulting in rapid and sustained tumor regression in mice without toxicity. Furthermore, in a xenograft model of multiple myeloma, treated mice showed resistance to tumor re-challenge indicating long-term persistence of TAC-T cells.
"These results will further illustrate the potential of TAC-T cells, both in terms of efficacy and safety but also with respect to TAC T-cell persistence, a key point under consideration in T cell therapy," said Paul Lammers, MD, MSc, President and Chief Executive Officer.
Triumvira also announces it is participating in the 11th Annual International Partnering Conference BioPharm America on September 5-6 and the 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies on September 4-5, both being held during Biotech Week Boston. For more information, or to set up a meeting with Triumvira at either conference email: [email protected].